While our work has formed the basis for ERVK3-1 to be considered a potential prognostic marker for GBM survival, development of a curated database with tumor samples sequenced for HERV and ERVK3-1 expression would be highly beneficial for future clinical application of our findings. The gene discussed is ERVK3-1; the disease is glioblastoma.